Brief: Mirum Pharmaceuticals Provides Azure Clinical Program Update For Brelovitug In Chronic Hepatitis Delta Virus
05/03/2026 13:03
March 5 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O: MIRUM PHARMACEUTICALS PROVIDES AZURE CLINICAL PROGRAM UPDATE FOR BRELOVITUG IN CHRONIC HEPATITIS DELTA VIRUS MIRUM PHARMACEUTICALS INC - TOPLINE AZURE-1 AND AZURE-4 DATA EXPECTED IN 2H 2026 MIRUM PHARMACEUTICALS INC: POTENTIAL BLA SUBMISSION AND LAUNCH IN U.S. FOR AZURE-1 AND AZURE-4 EXPECTED IN 2027 Source text: ID:nBw3xZBlSa Further company coverage: MIRM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX